- Home
- CULP vs MAIA Comparison
CULP vs MAIA Comparison
Compare CULP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CULP | MAIA |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CULP | MAIA |
|---|---|---|
| Price | $3.47 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.8K | ★ 936.4K |
| Earning Date | 12-10-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,919,000.00 | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $0.87 |
| 52 Week High | $5.94 | $2.74 |
Technical Indicators
Market Signals| Indicator | CULP | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 52.45 |
| Support Level | $3.42 | $1.13 |
| Resistance Level | $3.82 | $1.75 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 1.29 | 30.88 |
Price Performance
Historical ComparisonAbout CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.